See also section 14.7 for information about DTaP-IPV-HepB/Hib and DTaP-IPV vaccines.
A small proportion of individuals experience mild local symptoms following IPV. Injection site erythema is seen in 1–2 percent of infants, induration in 3–11 percent and pain in 14–29 percent. Similar local reactions are seen with combination vaccines.6 There is no poliovirus excretion following IPV.
In safety studies of IPV with combined vaccines, symptoms of irritability (14–37 percent), sleepiness (2–23 percent), diarrhoea (2–9 percent), vomiting (1–8 percent) and fever over 39oC (1–3 percent) have been reported after primary immunisation of infants (see the manufacturer’s data sheet for IPOL).
Serious adverse events are very rare following administration of the IPV currently manufactured. IPV-containing vaccines are licensed in more than 100 countries, and approximately 25 to 30 million newborn infants and approximately 15 million children, adolescents and adults receive them every year.6 There has been no association found with subsequent polio, Guillain-Barré syndrome, anaphylaxis or other serious reaction.